Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting muscarinic receptors to treat schizophrenia
Daniel J. Foster, Zoey Bryant, P. Jeffrey Conn
Behavioural Brain Research (2021) Vol. 405, pp. 113201-113201
Open Access | Times Cited: 67

Showing 1-25 of 67 citing articles:

Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
Robert A. McCutcheon, Richard S.E. Keefe, Philip McGuire
Molecular Psychiatry (2023) Vol. 28, Iss. 5, pp. 1902-1918
Open Access | Times Cited: 315
The schizophrenia syndrome, circa 2024: What we know and how that informs its nature
Rajiv Tandon, Henry A. Nasrallah, Schahram Akbarian, et al.
Schizophrenia Research (2023) Vol. 264, pp. 1-28
Open Access | Times Cited: 59
Antiemetic activity of abietic acid possibly through the 5HT3 and muscarinic receptors interaction pathways
Rubel Hasan, Abdulrahman Alshammari, Norah A. Albekairi, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 29
Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study
Colin Sauder, Luke Allen, Elizabeth Baker, et al.
Translational Psychiatry (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 63
Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic
Samantha E. Yohn, Peter J. Weiden, Christian C. Felder, et al.
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 12, pp. 1098-1112
Open Access | Times Cited: 60
A growing understanding of the role of muscarinic receptors in the molecular pathology and treatment of schizophrenia
Brian Dean, Geor Bakker, Hiroki R. Ueda, et al.
Frontiers in Cellular Neuroscience (2023) Vol. 17
Open Access | Times Cited: 26
New clues for the role of cerebellum in schizophrenia and the associated cognitive impairment
Pawan Faris, Doris Pischedda, Fulvia Palesi, et al.
Frontiers in Cellular Neuroscience (2024) Vol. 18
Open Access | Times Cited: 9
Overview of Novel Antipsychotic Drugs: State of the Art, New Mechanisms, and Clinical Aspects of Promising Compounds
Letizia Biso, Marco Carli, Marco Scarselli, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 85-85
Open Access | Times Cited: 1
The genetic relationships between brain structure and schizophrenia
Eva-Maria Stauffer, Richard A. I. Bethlehem, Lena Dorfschmidt, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 21
Novel Compounds in the Treatment of Schizophrenia—A Selective Review
Eva-Maria Tsapakis, Kalliopi Diakaki, Apostolos Miliaras, et al.
Brain Sciences (2023) Vol. 13, Iss. 8, pp. 1193-1193
Open Access | Times Cited: 18
Xanomeline-Trospium and Muscarinic Involvement in Schizophrenia
Neil S Kidambi, Omar H. Elsayed, Rif S. El‐Mallakh
Neuropsychiatric Disease and Treatment (2023) Vol. Volume 19, pp. 1145-1151
Open Access | Times Cited: 16
Current Findings and Potential Mechanisms of KarXT (Xanomeline–Trospium) in Schizophrenia Treatment
Ali Azargoonjahromi
Clinical Drug Investigation (2024) Vol. 44, Iss. 7, pp. 471-493
Closed Access | Times Cited: 6
A golden age of muscarinic acetylcholine receptor modulation in neurological diseases
Andrew B. Tobin
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 10, pp. 743-758
Closed Access | Times Cited: 6
A new era for schizophrenia drug development – Lessons for the future
Kiri Granger, Michael Sand, Sheryl Caswell, et al.
Drug Discovery Today (2023) Vol. 28, Iss. 7, pp. 103603-103603
Open Access | Times Cited: 14
The New Horizon of Antipsychotics beyond the Classic Dopaminergic Hypothesis—The Case of the Xanomeline–Trospium Combination: A Systematic Review
Octavian Vasiliu, Beatrice Budeanu, Mihai-Ștefan Cătănescu
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 610-610
Open Access | Times Cited: 5
Distinct Effects of Olanzapine Depot Treatment on Behavior and Muscarinic M1 Receptor Expression in the Triple‐Hit Wisket Rat Model of Schizophrenia
Gyöngyi Horváth, Eszter Ducza, Leatitia Gabriella Adlan, et al.
Genes Brain & Behavior (2025) Vol. 24, Iss. 1
Open Access
The role of rodent behavioral models of schizophrenia in the ongoing search for novel antipsychotics
Hugo Cano-Ramírez, Kurt L. Hoffman
Expert Opinion on Drug Discovery (2025), pp. 1-15
Closed Access
IUPHAR review: Drug Repurposing in Schizophrenia – An Updated Review of Clinical Trials
Jihan K. Zaki, Jakub Tomasik, Sabine Bahn
Pharmacological Research (2025), pp. 107633-107633
Open Access
Potential common targets of music therapy intervention in neuropsychiatric disorders: the prefrontal cortex-hippocampus -amygdala circuit (a review)
Yang Dan, Ying Xiong, Danghan Xu, et al.
Frontiers in Human Neuroscience (2025) Vol. 19
Open Access
A New Era of Muscarinic Acetylcholine Receptor Modulators in Neurological Diseases, Cancer and Drug Abuse
Helena Tsimpili, Grigoris Zoidis
Pharmaceuticals (2025) Vol. 18, Iss. 3, pp. 369-369
Open Access
Is muscarinic receptor agonist effective and tolerant for schizophrenia?
Xiaonan Guo, Rongshan Deng, Jianbo Lai, et al.
BMC Psychiatry (2025) Vol. 25, Iss. 1
Open Access
Xanomeline and Trospium: A Potential Fixed Drug Combination (FDC) for Schizophrenia-A Brief Review of Current Data.
Alok Singh
PubMed (2023) Vol. 19, Iss. 10-12, pp. 43-47
Closed Access | Times Cited: 12
M 1 -selective muscarinic allosteric modulation enhances cognitive flexibility and effective salience in nonhuman primates
Seyed A. Hassani, Adam Neumann, Jason K Russell, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 18
Open Access | Times Cited: 12
M1/M4 receptors as potential therapeutic treatments for schizophrenia: A comprehensive study
Lingsheng Fu, Yi Luo, Longyan Niu, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 105, pp. 117728-117728
Closed Access | Times Cited: 4
What is the neurobiology of schizophrenia?
Michael A. Cummings, Ai-Li W. Arias, Stephen M. Stahl
CNS Spectrums (2024) Vol. 30, Iss. 1
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top